Influence of estrogen plus testosterone supplementation on breast cancer

Archives of Internal Medicine
Roberta B NessJane A Cauley

Abstract

Concern that the use of exogenous testosterone may increase breast cancer risk coexists with rising use of this medication in the United States. We sought to examine the relationship between the use of estrogen plus testosterone (E + T) therapy (esterified estradiol plus methyltestosterone) and the occurrence of breast cancer. A total of 31,842 postmenopausal participants in the Women's Health Initiative Observational Study were followed for a mean of 4.6 years. At the 3-year visit, E + T users were compared with non-hormone therapy users for time to incident invasive breast cancer. Cox proportional hazards estimates were adjusted for known predictors of breast cancer including prior hormone use and screening mammography. Thirty five women using E + T at visit 3 developed invasive breast cancer. Use of E + T had a nonsignificant impact on invasive breast cancer risk (adjusted hazard ratio, 1.42; 95% confidence interval, 0.95-2.11). The most commonly used E + T preparation, Estratest, was associated with a significant elevation in invasive breast cancer (adjusted hazard ratio, 1.78; 95% confidence interval, 1.05-3.01). However, rates of breast cancer were lower in longer-term E + T users than in shorter-term E + T users. Althoug...Continue Reading

Citations

May 5, 2012·Women's Health·Kate Maclaran, Nick Panay
Nov 6, 2009·Breast Cancer Research : BCR·Constantine Dimitrakakis, Carolyn Bondy
Feb 19, 2011·Journal of the National Cancer Institute·Ghada N FarhatJennifer S Lee
Feb 22, 2012·Breast Cancer Research : BCR·Anne Zeleniuch-JacquotteKaren L Koenig
Dec 2, 2010·Human Fertility : Journal of the British Fertility Society·Kevan WylieFrederick Wu
Mar 8, 2012·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·Peter Kenemans, Marius J van der Mooren
May 8, 2013·Climacteric : the Journal of the International Menopause Society·S R Davis
Jun 4, 2013·The Journal of Steroid Biochemistry and Molecular Biology·Susan R Davis, Roisin Worsley
May 21, 2009·The Journal of Sexual Medicine·Susan R DavisRobin J Bell
Feb 7, 2012·The Journal of Sexual Medicine·Susan R Davis, Glenn D Braunstein
Oct 22, 2011·Steroids·Joanne Kotsopoulos, Steven A Narod
Sep 6, 2011·Endocrinology and Metabolism Clinics of North America·Constantine Dimitrakakis
Sep 6, 2011·Endocrinology and Metabolism Clinics of North America·Wendy Y Chen
Sep 21, 2010·Maturitas·Kevan WylieFrederick Wu
Sep 12, 2015·The Lancet. Diabetes & Endocrinology·Susan R Davis, Sarah Wahlin-Jacobsen
May 17, 2017·Climacteric : the Journal of the International Menopause Society·R F M VermeulenG G Kenter
Aug 1, 2010·Hormone Molecular Biology and Clinical Investigation·Abdulmaged M TraishAndre Guay
Sep 1, 2012·Expert Review of Endocrinology & Metabolism·Marie LebbeWiebke Arlt
Jan 9, 2015·Obstetrics and Gynecology·Sheryl A Kingsberg, Terri Woodard
Mar 19, 2011·Current Opinion in Endocrinology, Diabetes, and Obesity·Susan R Davis
Jun 27, 2019·Obstetrics and Gynecology·UNKNOWN American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Gynecology
Aug 17, 2011·Current Opinion in Endocrinology, Diabetes, and Obesity

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Ductal

Ductal carcinoma is a malignant neoplasm involving the ductal systems of any of a number of organs, such as the mammary glands, pancreas, prostate or lacrimal gland. Discover the latest research on ductal carcinoma here.